{"id":"W3203962015","doi":"10.1016/j.annonc.2021.08.1160","title":"647TiP PSMAddition: A phase III trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"Daiichi Sankyo Europe; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Eisai; AstraZeneca; Invitae; Myriad Genetics; Menarini Silicon Biosystems; Ipsen; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; Sierra Oncology; Endocyte; Taiho Pharmaceutical; Advanced Accelerator Applications; Sanofi; GlaxoSmithKline; Cardinal Health; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Prostate cancer; Oncology; Standard of care; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107845,0.001863003,0.002675564,0.0005178494,0.0003609667,0.001242849,0.001077183,0.001402588,0.008094063],"category_scores_gemma":[0.0009459119,0.0005998313,0.002164015,0.0005403128,0.001268315,0.001122535,0.0004550302,0.00370003,0.001667916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009923304,"about_ca_system_score_gemma":0.001703339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001532236,"about_ca_topic_score_gemma":0.003002908,"domain_scores_codex":[0.9996418,0.0001619358,0.00001745922,0.00007020771,0.00002354327,0.00008496284],"domain_scores_gemma":[0.9994311,0.0001233935,0.00009364935,0.00004655087,0.00002487619,0.0002803938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9493538,0.01057188,0.001187609,0.0004212691,0.001183708,0.00004043678,0.00006277095,0.0009909563,0.004692335,0.0002031982,0.001125518,0.03016649],"study_design_scores_gemma":[0.8195595,0.1744452,0.002830543,0.00003088641,0.0006672836,0.00005699466,0.00004238377,0.000668343,0.0006762938,0.000241237,0.0007563896,0.00002505562],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918569,0.002060358,0.0003984457,0.0006274045,0.0003438637,0.001182633,0.001007693,0.000144479,0.002378294],"genre_scores_gemma":[0.9881468,0.002148182,0.001144688,0.00091477,0.0003270584,0.001248181,0.002331983,0.00004231104,0.003696093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008094063,"threshold_uncertainty_score":0.02707738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09691843788467025,"score_gpt":0.4308888205358018,"score_spread":0.3339703826511315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}